These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 25391695)
1. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Yoshitake Y; Fukuma D; Yuno A; Hirayama M; Nakayama H; Tanaka T; Nagata M; Takamune Y; Kawahara K; Nakagawa Y; Yoshida R; Hirosue A; Ogi H; Hiraki A; Jono H; Hamada A; Yoshida K; Nishimura Y; Nakamura Y; Shinohara M Clin Cancer Res; 2015 Jan; 21(2):312-21. PubMed ID: 25391695 [TBL] [Abstract][Full Text] [Related]
2. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. Kono K; Iinuma H; Akutsu Y; Tanaka H; Hayashi N; Uchikado Y; Noguchi T; Fujii H; Okinaka K; Fukushima R; Matsubara H; Ohira M; Baba H; Natsugoe S; Kitano S; Takeda K; Yoshida K; Tsunoda T; Nakamura Y J Transl Med; 2012 Jul; 10():141. PubMed ID: 22776426 [TBL] [Abstract][Full Text] [Related]
3. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059 [TBL] [Abstract][Full Text] [Related]
5. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Fujiwara Y; Okada K; Omori T; Sugimura K; Miyata H; Ohue M; Kobayashi S; Takahashi H; Nakano H; Mochizuki C; Shimizu K; Yano M; Nakamura Y; Mori M; Doki Y Int J Oncol; 2017 May; 50(5):1655-1662. PubMed ID: 28393243 [TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485 [TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271 [TBL] [Abstract][Full Text] [Related]
8. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526 [TBL] [Abstract][Full Text] [Related]
9. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. Sundar R; Rha SY; Yamaue H; Katsuda M; Kono K; Kim HS; Kim C; Mimura K; Kua LF; Yong WP BMC Cancer; 2018 Mar; 18(1):332. PubMed ID: 29587677 [TBL] [Abstract][Full Text] [Related]
10. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850 [TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868 [TBL] [Abstract][Full Text] [Related]
12. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849 [TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Obara W; Eto M; Mimata H; Kohri K; Mitsuhata N; Miura I; Shuin T; Miki T; Koie T; Fujimoto H; Minami K; Enomoto Y; Nasu T; Yoshida T; Fuse H; Hara I; Kawaguchi K; Arimura A; Fujioka T Ann Oncol; 2017 Apr; 28(4):798-803. PubMed ID: 27998971 [TBL] [Abstract][Full Text] [Related]
15. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173 [TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149 [TBL] [Abstract][Full Text] [Related]
18. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Filipazzi P; Pilla L; Mariani L; Patuzzo R; Castelli C; Camisaschi C; Maurichi A; Cova A; Rigamonti G; Giardino F; Di Florio A; Asioli M; Frati P; Sovena G; Squarcina P; Maio M; Danielli R; Chiarion-Sileni V; Villa A; Lombardo C; Tragni G; Santinami M; Parmiani G; Rivoltini L Clin Cancer Res; 2012 Dec; 18(23):6485-96. PubMed ID: 23032742 [TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701 [TBL] [Abstract][Full Text] [Related]
20. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]